Biotech Values

[DewDiligence]

Certriad post-mortem: After thinking about this a little more, I suspect the pushback from the FDA was as simple as the FDA’s not being convinced that TriLipix + Crestor was significantly better than Crestor alone. For ABT and AZN to prove that adding TriLipix produced incremental efficacy in clinical outcomes would have been colossally expensive and taken too long to be worthwhile from a business standpoint.